

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **June 7, 2007**

## EXACT SCIENCES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-32179**

(Commission File Number)

**02-0478229**

(IRS Employer Identification No.)

**100 Campus Drive, Marlborough, Massachusetts**

(Address of Principal Executive Offices)

**01752**

(Zip Code)

Registrant's telephone number, including area code: **(508) 683-1200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 7.01 Regulation FD Disclosure.**

On June 7, 2007 EXACT Sciences Corporation issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On June 7, 2007 EXACT Sciences Corporation announced that it has been informed by officials of the American Cancer Society (the “ACS”) that the release of updated colorectal cancer screening guidelines, which are being drafted by the ACS and the U.S. Multi-Society Task Force, will not be issued in June. No additional information was available regarding when the process would be completed.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99.1 Press Release issued by the registrant on June 7, 2007, furnished herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 8, 2007

EXACT Sciences Corporation

By: /s/ Jeffrey R. Luber  
Jeffrey R. Luber  
Senior Vice President, Chief Financial Officer, General  
Counsel, Treasurer, and Secretary

## EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release issued by the registrant on June 7, 2007, furnished herewith.

---



## Press Release

---

### For further information:

Don M. Hardison  
President and CEO  
EXACT Sciences Corporation  
P: (508) 683-1200

---

### **EXACT Sciences Announces Colorectal Cancer Screening Guidelines Will Not Be Updated in June**

**MARLBOROUGH, Mass — (June 7, 2007)** - EXACT Sciences Corporation (NASDAQ: EXAS) announced today that the Company has been informed by officials of the American Cancer Society (ACS) that the release of updated colorectal cancer (CRC) screening guidelines, which are being drafted by the ACS and the U.S. Multi-Society Task Force (MSTF), will not be issued in June. No additional information was available regarding when the process would be completed.

As early as 2003, EXACT began interactions with the medical societies that are associated with the guidelines process. Since then, the Company has provided a breadth of clinical information regarding stool-based DNA (sDNA) screening, including the data demonstrating sDNA's sensitivity for detecting colorectal cancer, the high patient acceptability and compliance, as well as the cost-effectiveness of this approach.

"We have been careful to follow the process that was described in the original CRC screening guidelines published by a consortium of gastroenterology societies in 1997(1) regarding the evaluation of new screening technologies," said Don Hardison, President and CEO, EXACT Sciences Corporation. "In our supporting documentation, we have followed these criteria, providing what we believe is convincing evidence that sDNA screening: 1) has 'comparable performance', with published studies that have shown superior performance when compared to other tests for detecting cancer; 2) is 'equally acceptable to patients', with published studies demonstrating high patient acceptability and improved compliance; and 3) has 'comparable or lower complication rates and costs', with published studies demonstrating the cost-effectiveness of sDNA testing."

Mr. Hardison continued, "We believe that sDNA technology has met each of these criteria based on nearly a decade of clinical data, patient acceptability and cost-effectiveness evidence supportive of sDNA screening. This is why we remain optimistic that sDNA will be included in the screening guidelines when the process is completed."

Further information provided to the ACS and the MSTF in 2005, included data from the large, multi-center study published in *The New England Journal of Medicine* in 2004(2) demonstrating stool-based DNA's superior performance over the most widely prescribed fecal occult blood test — a test that is included in screening guidelines. Data was also submitted from EXACT's most recent study showing 88 percent sensitivity of the

---

Company's newest version of the technology for detecting CRC, as reported in the *Journal of Clinical Hepatology and Gastroenterology* in January, 2007.(3)

"Although we are disappointed with the delay, we also remain very appreciative of the positive impact of the ACS and the MSTF in driving innovations in cancer prevention, detection and treatment and we look forward to working with them as they complete this important guidelines process," concluded Mr. Hardison.

### **About Colorectal Cancer**

Colorectal cancer is the most deadly cancer among non-smoking men and women in the U.S., and the second most deadly cancer overall. Annually, there are nearly 154,000 CRC cases diagnosed and 52,000 deaths due to this disease(4). It is estimated that roughly one-third of CRC-related deaths could be saved if more people underwent regular screening. Early diagnosis results in a greater than 90 percent, five-year survival rate. The American Cancer Society has set a goal of increasing to 75 percent the proportion of people over the age of 50 who have CRC screening consistent with the ACS guidelines by the year 2015.

### **About EXACT Sciences Corporation**

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America<sup>®</sup> Holdings (LabCorp<sup>®</sup>) for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will help enable detection of colorectal cancer so that more people can be effectively treated. EXACT Sciences is based in Marlborough, Mass. PreGen-Plus<sup>™</sup>, the non-invasive colorectal screening test offered by LabCorp, has not been approved or cleared by the Food & Drug Administration.

- 
- (1) Winawer SJ, et al. Colorectal Cancer Screening: Clinical Guidelines and Rationale. *Gastroenterology* 1997;112:594-642.
  - (2) Imperiale TF, et al. Fecal DNA versus Fecal Occult Blood for Colorectal Cancer Screening in an Average-Risk Population. *The New England Journal of Medicine* 2004;351:2704-2714.
  - (3) Itzkowitz SH, et al. Improved Fecal DNA Test for Colorectal Cancer Screening. *Clinical Gastroenterology and Hepatology* 2007;5:111-117.
  - (4) American Cancer Society, Facts & Figures, 2007

###

---